medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 3

<< Back Next >>

Ann Hepatol 2013; 12 (3)

The effect of celecoxib on the development of diethylnitrosamine-induced liver tumors in rats

Widholzer GL, Alves MÁ, Menti E, Borba VF, Zambam MÁ, Porawski M, Hartmann A, Ramos RC

Language: English
References: 48
Page: 425-433
PDF size: 124.08 Kb.


ABSTRACT

Background/aims. Hepatocellular carcinoma is one of the most commonly diagnosed malignant tumors in the world, and it typically has a poor prognosis. Extensive studies have examined the effects of non-steroidal anti-inflammatory drugs selective to COX-2 on the chemoprevention of various tumors. The objective of this study is to observe the effect of celecoxib on the development of liver tumors in rats. Material and methods. Hepatocellular carcinoma was induced in a group of 75 rats with the carcinogen diethylnitrosamine. The animals were divided into 5 groups. Three groups received various doses of celecoxib, one group received indomethacin, and a control group received no non-steroidal selective anti-inflammatory drugs. Results. The experimental model was considered to be successful because 78% of the rats in the control group developed liver tumors. The number of neoplastic lesions was similar among the celecoxib, indomethacin and control groups, although the nodule diameter of the lesions was smaller in the celecoxib group. Better results were observed in animals that received celecoxib at doses of 6 and 9 mg/kg/ day; 4 rats in these groups did not show any neoplastic histological lesions, and a greater proportion of the nodules in the other animals in these groups were benign than in the groups that did not use celecoxib. Conclusions. These results suggest that celecoxib may play a role in modifying the natural history of hepatocellular carcinoma development.


REFERENCES

  1. Llovet JM, Bruix J. Novel advancement in the management of hepatocellular carcinoma in 2008. J Hepatology 2008; 48: S20-S37.

  2. Roberts LR. Sorafenib in liver cancer; just the beginning. New Engl J Med 2008; 359: 420-2.

  3. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007; 102: 1661-70.

  4. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-44.

  5. Carrilho F, Kikuchi L, Branco F, Gonçalves CS, Mattos AA; Study Group Brazilian HCC. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Clinics 2010; 65: 1285-90.

  6. Gabibbo G, Enea M, Atanasio M, Bruix J, Craxí A, Cammà C. A meta-analys of survival rates of untreated patients in randomized clinical trias of hepatocellular carcinoma. Hepatology 2010; 51: 1274-83.

  7. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocelular carcinoma. Gastroenterology 2008; 134: 1752-63.

  8. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.

  9. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008: 359: 378-90.

  10. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410-26.

  11. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 407-12.

  12. Koga H, Sakisaka S, Ohishi M, Kamaguchi T, Taniguchi E, Sasatomi K, Harada M, et al. Expression of cyclooxygenase- 2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29: 688-95.

  13. Cui W, Yu CH, Hu KQ. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 2005; 11: 8213-21.

  14. Koga H. Hepatocellular Carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer 2003; 98: 661-7.

  15. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Tumor Review. Cancer Treatment Reviews 2006; 32: 28-44.

  16. Cervello M, Montalto G. Cyclooxygenase in hepatocellular carcinoma. World J Gastroenterol 2006; 12: 5113-21.

  17. Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L, D’Alessandro N, et al. Cycloxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma. A Immunohistochemical study. Steroid Enzymes and Cancer. Ann NY Acad Sci 2009; 1155: 293-9.

  18. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through AKT activation: Evidence for AKT inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756-68.

  19. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006; 207: 261-70.

  20. Malka D, Pacault V, De Baere T, Ducreux M, Boige V. Antitumoral effect of celecoxib in hepatocellular carcinoma. J Clin Oncol 2005; 23: 4805-6.

  21. Kern MA, Schubert D, Sahi D, Schöneweiss MM, Moll I, Haugg AM, Dienes HP, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002; 36: 885-94.

  22. Baek JY, Hur W, Wang JS, Bae SH, Yoon SK. Selective COX- 2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol 2007; 13: 1175-81.

  23. Park JW, Park JE, Lee JA, Lee CW, Kim CM. Cyclooxygenase- 2 (COX-2) is directly involved but not decisive in proliferation of human hepatocellular carcinoma cells. J Cancer Res Clin Oncol 2006; 132: 184-92.

  24. Cao B, Chen XP, Zhu P, Ding L, Guan J, Shi ZL. Inhibitory effect of interferon-á-2b on expression of yclooxygenase- 2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. World J Gastroenterol 2008; 14: 6802-7.

  25. Al-Rejaie SS, Aleisa AM, Al-Yahya AA, Bakheet SA, Alsheikh A, Fatani AG, Al-Shabanah OA, et al. Progression of diethylnitrosamine- induced hepatic carcinogenesis in carnitinedepleted rats. World J Gastroenterol 2009; 15: 1373-80.

  26. Wei M, Hamoud AS, Yamaguchi T, Kakehashi A, Morimura K, Doi K, Kushida M, et al. Potassium Bromate Enhances NEthyl- NHydroxyethylnitrosamine–Induced Kidney Carcinogenesis Only at High Doses in Wistar Rats: Indication of the Existence of an Enhancement Threshold. Toxicol Pathol 2009; 37: 983-91.

  27. Goldin JR, Raymundo MM. Pesquisa em saúde e direito dos animais. Porto Alegre HCPA 1997.

  28. Johnson SJ, Burr AW, Toole K, Dack CL, Mathew J, Burt AD. Macrophage and hepatic stellate cell responses during experimental hepatocarcinogenesis. J Gastroenterol Hepatol 1998; 13: 145-51.

  29. Salcido-Neyoy ME, et al. Celecoxib enhances the detoxification of diethylnitrosamine in rat liver cancer. World J Gastroenterol 2009; 15: 2345-50.

  30. Sozer S, Diniz G, Lermioglu F. Effects of Celecoxib in Young Rats: Histopathological Changes in Tissues and Alterations of Oxidative Stress/Antioxidant Defense System. Arch Pharm Res 2011; 34: 253-9.

  31. Buege JA, Aust SD. Microssomal lipid peroxidation. Meth Enzymol 1978; 52: 302-9.

  32. Lowry OH, Rosenbrough MJ, Farr AL, Randall RL. Protein measurement with the foline reagent. J Biol Chem 1951; 193: 265.

  33. Simile MM, De Miglio MR, Calvisi D, Muroni MR, Frau M, Asara G, Daino L, et al. Long-term dehydro-epiandrosterone and 16α-fluoro-5-androsten-17-one administration enhances DNA synthesis and induces expression of c-fos and c- Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine-initiated rats. Carcinogenesis 2001; 21: 301-8.

  34. Stewart HL, Willians G, Keysser CH, Lombart LS, Montali RJ. Histological typing of liver tumors of the rat. J Natl Cancer Inst 1980; 64: 177-206.

  35. Lang TA, Secic M. How to report statistics in medicine. Philadelphia: ACP-American College of Physicians; 1997, p. 1-365.

  36. Tanaka T, Kojima T, Okumura A, Sugie S, Mori H. Inhibitory effect of the non-steroidal anti-inflammatory drugs, indomethacin and piroxican, on 2-acetylaminofluorene-induced hepatocarcinogenesis in male ACI/N rats. Cancer Lett 1993; 68: 111-8.

  37. Hu KQ. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 2002; 139: 234-43.

  38. Bae SH, Jung ES, Park YM, Kim BS, Kim BK, Kim DG, Ryu WS. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001; 7: 1410-8.

  39. Liu NB, Peng T, Pan C, Yao YY, Shen B, Leng J. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. World J Gastroenterol 2005; 11: 6281-7. PMID: 16419156.

  40. Fantappiè O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, et al. The MRD phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 2002; 35: 843-52.

  41. Dubois RN. Cyclooxygenase-2 and hepatocellular carcinoma: is it a target for prevention? Clin Cancer Res 2001; 7: 1110-1.

  42. Bannasch P. Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular, and metabolic changes. Prog Liver Dis 1996; 14: 161-97.

  43. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 2nd Ed. Oxford: Clarendon Press; 1989, p. 332-41.

  44. Rhoden CR, Rhoden EL, Pereira-Lima LM, Mauri M, Lucas ML, Pereira-Lima JE, Zettler CG, et al. The effects of the allopurinol in hepatic ischemia and reperfusion: experimental study in rats. Eur Surg Res 2000; 569: 215-22.

  45. Rhoden CR, Rhoden EL, Pereira-Lima LM, Kalil AN, Lucas ML, Mauri M, Pereira-Lima JE, et al. The effects of ischemia and reperfusion on oxidative stress in hepatic cirrhosis induced by carbon tetrachloride in rats. Kobe J Med Sci 2000; 46: 171-80.

  46. Yu J, Tang BD, Leung WK, To KF, Bai AHC, Zeng ZR, Ma PK, et al. Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: Implications on chemoprevention. World J Gastroenterol 2005; 11: 41-5.

  47. Xu Z, Zhang M, Lv X, Xiang D, Zhang X, Chen L. The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway. Biochem Cell Biol 2010; 88: 603-9.

  48. Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R. P-Glycoprotein mediates celecoxib-induced apoptosis: multiple drug-resistant cell lines. Cancer Res 2007; 67: 4915-23.




2020     |     www.medigraphic.com